Edwards Lifesciences Corporation $EW Position Lessened by Tocqueville Asset Management L.P.

Key Points

• Tocqueville Asset Management L.P. reduced its stake in Edwards Lifesciences Corporation by 4.9%, selling 4,085 shares, leaving them with holdings worth approximately $5.69 million.
• Insiders have sold a total of 17,134 shares over the past 90 days, representing a combined value of $1.31 million, and insiders now own only 1.29% of the company's stock.
• Edwards Lifesciences reported a 12-month revenue increase of 11.9% and a quarterly earnings per share of $0.67, surpassing the consensus estimate by $0.05.

Tocqueville Asset Management L.P. trimmed its stake in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 4.9% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 78,485 shares of the medical research company's stock after selling 4,085 shares during the quarter. Tocqueville Asset Management L.P.'s holdings in Edwards Lifesciences were worth $5,689,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. American Century Companies Inc. boosted its position in shares of Edwards Lifesciences by 9.3% in the 1st quarter. American Century Companies Inc. now owns 1,274,184 shares of the medical research company's stock valued at $92,353,000 after purchasing an additional 108,127 shares during the period. Ethic Inc. boosted its position in shares of Edwards Lifesciences by 39.1% in the 1st quarter. Ethic Inc. now owns 56,168 shares of the medical research company's stock valued at $4,037,000 after purchasing an additional 15,775 shares during the period. Sector Gamma AS boosted its position in shares of Edwards Lifesciences by 24.2% in the 1st quarter. Sector Gamma AS now owns 123,000 shares of the medical research company's stock valued at $8,915,000 after purchasing an additional 24,000 shares during the period. Element Capital Management LLC acquired a new stake in shares of Edwards Lifesciences in the 1st quarter valued at about $2,781,000. Finally, Dimensional Fund Advisors LP boosted its position in shares of Edwards Lifesciences by 6.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 3,196,992 shares of the medical research company's stock valued at $231,676,000 after purchasing an additional 201,784 shares during the period. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Trading Down 0.3%

NYSE EW traded down $0.2320 during trading hours on Thursday, hitting $81.1580. 4,021,823 shares of the company's stock were exchanged, compared to its average volume of 4,506,225. The business's 50 day moving average is $77.35 and its 200-day moving average is $74.54. Edwards Lifesciences Corporation has a 12-month low of $64.00 and a 12-month high of $83.00. The firm has a market capitalization of $47.65 billion, a P/E ratio of 11.68, a price-to-earnings-growth ratio of 3.81 and a beta of 1.08. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.62 by $0.05. The company had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The firm's revenue was up 11.9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.70 earnings per share. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, VP Donald E. Bobo, Jr. sold 2,570 shares of the stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $77.40, for a total value of $198,918.00. Following the completion of the sale, the vice president owned 50,356 shares in the company, valued at approximately $3,897,554.40. This trade represents a 4.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Daniel J. Lippis sold 4,114 shares of the stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $79.46, for a total value of $326,898.44. Following the completion of the sale, the vice president owned 22,002 shares of the company's stock, valued at approximately $1,748,278.92. This trade represents a 15.75% decrease in their position. The disclosure for this sale can be found here. Insiders sold 24,584 shares of company stock worth $1,897,762 over the last three months. 1.29% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of analysts recently issued reports on EW shares. William Blair raised Edwards Lifesciences to a "strong-buy" rating in a research report on Friday, July 25th. Mizuho increased their price objective on Edwards Lifesciences from $87.00 to $95.00 and gave the stock an "outperform" rating in a research report on Friday, July 25th. Citigroup reaffirmed a "buy" rating and set a $95.00 price objective (up from $84.00) on shares of Edwards Lifesciences in a research report on Thursday, May 22nd. Wells Fargo & Company increased their price objective on Edwards Lifesciences from $84.00 to $88.00 and gave the stock an "overweight" rating in a research report on Thursday, August 7th. Finally, BTIG Research raised Edwards Lifesciences from a "neutral" rating to a "buy" rating and set a $100.00 price objective for the company in a research report on Tuesday, July 29th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Edwards Lifesciences currently has a consensus rating of "Moderate Buy" and an average target price of $85.90.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.